DOCSLIB.ORG

Piperidine AC-002 34381-68-5 Acebutolol Hydrochlorid

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Piperidine AC-002 34381-68-5 Acebutolol Hydrochlorid Email: [email protected] Catalog No. CAS No. Product Name AC-001 154235-83-3 1-(6-quinoxalinylcarbonyl)-Piperidine AC-002 34381-68-5 Acebutolol Hydrochloride AC-003 5438-68-6 O-acetyl mandelic acid AC-004 5080-50-2 Acetyl-L-Carnitine Hydrochloride AC-006 61985-25-9 4-Acetylimidazole AC-007 57756-36-2 4-Acetyl-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine AC-008 99-96-7 4-Hydroxybenzoic acid AC-009 51037-30-0 Acipimox AC-011 39269-10-8 1,3-Adamantanedicarboxylic acid AC-012 106941-25-7 Adefovir AC-013 50-42-0 Adiphenine Hydrochloride AC-014 56-41-7 L-Alanine AC-015 54965-21-8 Albendazole AC-016 54029-12-8 Albendazole Sulfoxide AC-017 26750-81-2 Alibendol AC-018 80863-62-3 Alitame AC-019 315-30-0 Allopurinol AC-020 481-72-1 Aloeemodin AC-021 850649-62-6 Alogliptin Benzoate AC-022 122852-69-1 Alosetron Hydrochloride AC-023 850-52-2 ALTRENOGEST AC-024 23828-92-4 Ambroxol Hydrochloride AC-025 1750-42-1 3-Amino isoxazole AC-026 149934-21-4 9-Amino minocycline sulphate AC-027 98-16-8 M-amino trifluorotoluene AC-028 455-14-1 4-Aminobenzotrifluoride AC-029 55716-66-0 4-aminobenzocyclobutene AC-030 126325-50-6 3-Amino-2-bromo-4-picoline AC-031 1072-97-5 2-Amino-5-bromopyridine AC-032 84249-14-9 2-Amino-4-bromopyridine AC-033 96-20-8 2-Amino-1-butanol AC-034 13325-10-5 4-Amino-1-butanol AC-035 60-32-2 6-Aminocaproic acid AC-036 121-30-2 4-Amino-6-chloro-benzene-1,3-disulfonic acid diamide Hangzhou APIChem Technology Co., Limited Email: [email protected] Website: www.apichemistry.com Email: [email protected] Catalog No. CAS No. Product Name AC-037 95-24-9 2-Amino-6-chlorobenzothiazole AC-038 20776-67-4 2-Amino-5-chloro-3-methylbenzoic acid AC-039 3993-78-0 2-Amino-4-Chloropyrimidine AC-040 3814-46-8 2-Aminocycloheptanecarboxylic acid AC-041 75081-40-2 (±)-2-Amino-cyclohexanecarboxylic acid AC-042 27489-62-9 trans-4-Aminocyclohexanol AC-043 156732-15-9 (2S,3S,5S)-5-amino-2-(dibenzylamino)-1,6-diphenyl hexan-3-ol AC-044 120068-79-3 5-Amino-1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cycano pyrazole AC-045 40324-15-3 3-Amino-4-ethylpyrazole AC-046 344-80-9 2-Amino-2'-fluoro-5-nitrobenzophenone AC-047 2247-88-3 4-Amino-3-fluoropyridine AC-048 73616-27-0 5-amino-1-(β-hydroxyethyl)pyrazole AC-049 2280-48-0 (R)-2-Amino-3-Hydroxy-3-Methylbutanoic Acid AC-050 6320-39-4 3-Amino-4-hydroxypyridine AC-051 7720-39-0 2-aminoimidazole AC-052 6967-12-0 6-Amino-1H-indazole AC-053 129488-10-4 5-Amino-1H-indazole-1-carboxylic acid, 1,1 dimethyl ethyl ester AC-054 106-60-5 5-Aminolevulinate AC-055 3880-88-4 2-amino-5-methoxytetralin Hydrochloride AC-056 2840-04-2 5-Amino-2-methyl-benzoic acid AC-057 2026-48-4 (S)-(+)-2-Amino-3-methyl-1-butanol AC-058 130912-52-6 (+/-)-3-(Aminomethyl)-5-Methylhexanoic acid AC-059 80082-65-1 (2S-trans)-3-amino-2-methyl-4-oxoazetidine-1-sulfonic acid AC-060 96886-55-4 (S)-2-Amino-2-Methyl-4-Pentenoic Acid AC-061 1904-31-0 3-amino-1-methylpyrazole AC-062 17557-67-4 2-Amino-6-methylsulfonylbenzothiazole AC-063 1588-83-6 4-Amino-3-nitro-benzoic acid AC-064 4570-45-0 2-Amino-oxazole AC-065 137281-39-1 4-[2-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)- ethyl]-benzoic acid AC-066 147027-10-9 (2R,5R)-5-(4-Amino-2-Oxo-2H-Pyrimidin-1-Yl)-[1,3]Oxathiolane-2 -Carboxylic Acid,2S-Isopropyl-5-R-Methyl-1R-Cyclohexyl Ester Hangzhou APIChem Technology Co., Limited Email: [email protected] Website: www.apichemistry.com Email: [email protected] Catalog No. CAS No. Product Name AC-067 5339-94-3 2-amino-phenethylalcohol AC-068 54060-30-9 3-Aminophenylacetylene AC-069 36725-28-7 6-(4-Amino-phenyl)-5-methyl-4,5-dih ydro-2H-pyridazin-3-one AC-070 101328-85-2 (R)-6-(4-Aminophenyl)-5-Methylpyridazin-3(2H)One AC-071 82769-76-4 (S)-3-Amino-3-phenylpropan-1-ol AC-072 13822-56-5 3-Aminopropyltrimethoxysilane AC-073 24242-20-4 5-Amino-2-pyridinecarboxylic acid AC-074 59315-44-5 3-amino-pyridin-2-ol AC-075 86299-47-0 (Z)-2-amino-alpha-[1-(tert-butoxycarbonyl)]-1-1-methylethoxyimin o-4-thiazoleacetic acid AC-076 2150-55-2 2-Amino-4-thiazolinic acid AC-077 73150-67-1 2-(2-Aminothiazol-4-yl) glyoxylic acid AC-078 19774-82-4 Amiodarone hydrochloride AC-079 111470-99-6 Amlodipine besylate AC-080 78613-38-4 Amorolfine Hydrochloride AC-081 1156-92-9 4-Androstenediol AC-082 51025-85-5 Arbekacin AC-083 74-79-3 Arginine AC-084 63358-49-6 Aspoxicillin Trihydrate AC-085 156311-83-0 (7-Azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate AC-086 112626-50-3 3-Azabicyclo[3.3.0]octane Hydrochloride AC-088 272-49-1 4-Azaindole AC-089 N/A 4-(2-Azepan-1-yl-ethoxy)-benzaldehyde AC-090 N/A 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-5-benzyloxy-2-(4-benzyloxy- phenyl)-3-methyl-1H-indole AC-091 N/A [4-(2-Azepan-1-yl-ethoxy)-phenyl]-methanol AC-092 45347-82-8 Azetidin-3-ol AC-093 117772-70-0 Azithromycin AC-094 2446-83-5 Azodicarboxylic Acid Diisopropyl Ester AC-095 4693-47-4 Azopentanon-C AC-096 27589-33-9 Azosemide AC-097 104757-53-1 Barnidipine Hydrochloride Hangzhou APIChem Technology Co., Limited Email: [email protected] Website: www.apichemistry.com Email: [email protected] Catalog No. CAS No. Product Name AC-098 2390-63-8 Basic violet 11 AC-099 198481-33-3 Bazedoxifene acetate AC-100 195730-31-5 benzocyclobutene-4-boronic acid AC-101 3469-06-5 benzocyclobutenone AC-102 5350-57-2 Benzophenone hydrozone AC-103 3468-01-7 4H-1-Benzopyran-8-carboxylicacid, 3-methyl-4-oxo-2-phenyl- AC-104 89604-91-1 S-2-Benzothiazolyl(Z) -2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyimino thioacetate AC-105 611-73-4 Benzoyl formoic acid AC-106 7697-46-3 2-benzoylpyrrole AC-107 111865-47-5 Benzyl trimethyl ammonium tribromide AC-108 N/A (S)-3-benzylcarbonyl-5-oxo-4-oxazolidineacetic acid AC-109 93779-31-8 (S)-Benzyl endo, cis-2-azabicyclo [3,3,0]octanecarboxylate Hydrochloride AC-110 51388-20-6 4-Benzyloxyaniline Hydrochloride AC-111 N/A 5-Benzyloxy-2-(4-benzyloxy-phenyl)-1-[4-(2-bromo-ethoxy)-benz yl]-3-methyl-1H-indole AC-112 N/A 2-{4-[5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-indol-1-ylmet hyl]-phenoxy}-ethanol AC-114 198479-63-9 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1H-indole AC-115 N/A {4-[5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-indol-1-ylmethy l]-phenoxy}-acetic acid ethyl ester AC-116 35081-45-9 4'-(Benzyloxy)-2-bromopropiophenone AC-117 2086-83-1 Berberine AC-118 633-65-8 Berberine hydrochloride AC-119 1247-42-3 Betapar AC-120 181695-72-7 Valdecoxib AC-121 120410-24-4 biapenem AC-122 N/A Bicyclo[4.2.0]octa-1(6),2,4-triene-2-carboxylic acid AC-123 82657-04-3 Bifenthrin AC-124 58-85-5 Biotin AC-125 138401-24-8 [1.1′-Biphenyl]-2-carbonitrile-4-[(2-butyl-4-oxo-1.3-diazaspiro [4.4]non-1-en-3-yl)methyl] Hangzhou APIChem Technology Co., Limited Email: [email protected] Website: www.apichemistry.com Email: [email protected] Catalog No. CAS No. Product Name AC-126 16150-45-1 1,3-bis(2-ethoxycarbonylchromon-5-yloxy)-2-hydroxypropan; Diethyl cromoglycate AC-127 N/A 2-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-isoindole-1,3-dione AC-128 3197-06-6 N,N-BIS(2-HYDROXYETHYL)ETHYLENEDIAMINE AC-129 5538-94-3 Bisoctyl dimethyl ammonium chloride AC-131 91188-13-5 3-Boc-aminoazetidine AC-132 98737-29-2 (2R,3S)-N-Boc-3-amino-1,2-epoxy-4-phenylbutane AC-133 166104-20-7 1-Boc-5-Aminoindole AC-134 135632-53-0 4-(Boc-aminomethyl) piperidine AC-135 66605-57-0 (S)-2-(Boc-amino)-3-phenyl-1-propanol AC-136 625471-18-3 (S)-N-Boc-3-aminopiperidine AC-137 73286-70-1 N-Boc-2,5-dihydropyrrole AC-138 4530-20-5 N-Boc-L-glycine AC-139 109431-87-0 (R)-N-boc-3-hydropyrrolidine AC-141 13726-69-7 Boc-L-Hyp-OH AC-142 147539-41-1 N-Boc-4-methylaminopieridine AC-143 N/A Boc-L-phe(3,4-OH2)-OH AC-144 124443-68-1 N-BOC-Piperidine-4-carboxylic acid methyl ester AC-145 35150-07-3 DL-1-Boc-prolinamide AC-146 122684-34-8 1-Boc-pyrrolidine-3-carboxamide AC-147 140148-70-5 (S)-1-Boc-pyrrolidine-3-carboxylic acid AC-148 147536-97-8 Bosentan AC-149 91714-93-1 Bromfenac Sodium AC-150 5003-71-4 3-Brominepropylaminehydrobromide AC-151 622-88-8 4-Bromo Phenyl Hydrazine Hydrochloride AC-152 139042-59-4 2-BROMO-5-ACETYLPYRIDINE AC-153 615-36-1 2-Bromoaniline AC-154 21120-91-2 1-bromobenzocyclobutene AC-155 73443-85-3 4-Bromo-3H-benzothiazol-2-one AC-156 19472-74-3 2-bromobenzyl cyanide AC-157 1073-39-8 3-Bromo-bicyclo[4.2.0]octa-1,3,5-triene AC-158 60633-25-2 2-Bromo-4-Chloroanisole AC-159 81682-38-4 2-bromo-5-chlorophenylacetic acid Hangzhou APIChem Technology Co., Limited Email: [email protected] Website: www.apichemistry.com Email: [email protected] Catalog No.
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • (Esi Scheme) Laxminagar, Ajmer Road, Jaipur-302006
    DIRECTORATE, MEDICAL & HEALTH SERVICES, (E.S.I. SCHEME) LAXMINAGAR, AJMER ROAD, JAIPUR-302006 Tel/Fax 0141-2223572,www.health.rajasthan.gov.in/esi E-Mail [email protected],[email protected] Ref. No. F434/ESI/Store/LabEmp/2017/5540 Dated:01/11/2017 E- Tender Document For “E- Tender forAnalysis of Drugs, Cotton, Gauzes, Bandage & Other items” For The Office of the Director cum Ex-officio Dy. Secretary, Medical & Health Services ESI Scheme Rajasthan, Laxmi Nagar, Ajmer Road, Jaipur & attached ESIS Institutions in Rajasthan ( for the period of two years from the date of award. ) ( Non-transferable ) Price of Tender Document Rs. 2000/- Last date & time of submission of Technical & Financial Bids is 11.12.17 at 1:30 pm Date & time of online opening of Technical Bid is 11.12.17 at 3:00 pm Visit Us At http://sppp.raj.nic.in, www.dipronline.org, http://eproc.rajasthan.gov.in, www.health.rajasthan.gov.in/esi Our Address: DIRECTORATE, MEDICAL & HEALTH SERVICES, (E.S.I. SCHEME) LAXMINAGAR, AJMER ROAD, JAIPUR-302006 1/71 DIRECTORATE, MEDICAL & HEALTH SERVICES, (E.S.I. SCHEME) LAXMINAGAR, AJMER ROAD, JAIPUR-302006 Tel/Fax 0141-2223572,www.health.rajasthan.gov.in/esi E-Mail [email protected],[email protected] Ref.No.F434/ESI/Store/LabEmp/2017/ 5540 Dated:01/11/2017 E-bids in two separate bids (Technical & Financial) for the Empanelment of Analytic Testing Laboratories For The Test and Analysis of drugs, cotton, bandage, gauze & other items. Brief Details of E-Tender Estimated Cost : Rs 50 lacs EMD (Bid Security)Rs 100000/- RISL processing fees Rs 1000/- Cost of the Tender Document Rs 2000/- Performance Security 5% of contract value Services Required:- The service of analysis of drugs, cotton, gauze, bandages & other items are required in the office of the Director cum Ex- officio Dy.
    [Show full text]
  • Interactions with PBC Agents
    www.hep-druginteractions.org Interactions with PBC Agents Charts created March 2020. Full information available at www.hep-druginteractions.org Page 1 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. Obeticholic Ursodeoxycholic Obeticholic Ursodeoxycholic Obeticholic Ursodeoxycholic Acid Acid Acid Acid Acid Acid Anaesthetics & Muscle Relaxants Antibacterials (continued) Antidepressants Bupivacaine Cloxacillin Agomelatine Cisatracurium Dapsone Amitriptyline Isoflurane Delamanid Bupropion Ketamine Ertapenem Citalopram Nitrous oxide Erythromycin Clomipramine Propofol Ethambutol Desipramine Thiopental Flucloxacillin Desvenlafaxine Tizanidine Gentamicin Dosulepin Analgesics Imipenem Doxepin Aceclofenac Isoniazid Duloxetine Alfentanil Escitalopram Aspirin Levofloxacin Linezolid Fluoxetine Buprenorphine Fluvoxamine Lymecycline distribution. Celecoxib Imipramine Meropenem Codeine Lithium Methenamine Dexketoprofen Maprotiline Metronidazole Dextropropoxyphene Mianserin Moxifloxacin Diamorphine Milnacipran Diclofenac Nitrofurantoin only. Not for distribution. for only. Not Mirtazapine Diflunisal Norfloxacin Moclobemide Dihydrocodeine Ofloxacin Nefazodone Etoricoxib Penicillin V Nortriptyline Fentanyl Piperacillin Paroxetine Flurbiprofen Pivmecillinam Sertraline Hydrocodone use ersonal Pyrazinamide Tianeptine Hydromorphone Rifabutin Trazodone Ibuprofen Rifampicin
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.498,431 B2 Xu Et Al
    USOO9498431B2 (12) United States Patent (10) Patent No.: US 9.498,431 B2 Xu et al. (45) Date of Patent: Nov. 22, 2016 (54) CONTROLLED RELEASING COMPOSITION 7,053,134 B2 * 5/2006 Baldwin et al. .............. 522,154 2004/0058056 A1 3/2004 Osaki et al. ................... 427.2.1 (76) Inventors: Jianjian Xu, Hefei (CN); Shiliang 2005/0037047 A1 2/2005 Song Wang, Hefei (CN); Manzhi Ding 2007/0055364 A1* 3/2007 Hossainy .................. A61F 2/82 s: s s 623, 1.38 Hefei (CN) 2008/0274194 A1* 11/2008 Miller .................... A61K 9.146 424/489 (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C. 154(b) by 0 days. CN 1208.610 A 2, 1999 (21) Appl. No.: 13/133,656 EP O251680 A2 1, 1988 JP S63-22516. A 1, 1988 JP H1O-310518 A 11, 1998 (22) PCT Filed: Dec. 10, 2009 WO 96,10395 A1 4f1996 WO WO 2005.000277 A1 * 1, 2005 (86). PCT No.: PCT/CN2009/075468 WO 2007 115045 A2 10, 2007 WO 2008/OO2657 A2 1, 2008 S 371 (c)(1), WO 2008OO2657 A2 1, 2008 (2), (4) Date: Jun. 9, 2011 WO 2008041246 A2 4/2008 (87) PCT Pub. No.: WO2010/066203 OTHER PUBLICATIONS PCT Pub. Date: Jun. 17, 2010 Crowley and Zhang, Pharmaceutical Application of Hot Melt Extru (65) Prior Publication Data sion: Part I, Drug Development and Industrial Pharmacy, 2007. 33:909-926.* US 2011/024.4043 A1 Oct. 6, 2011 The Use of Poly (L-Lactide) and RGD Modified Microspheres as Cell Carriers in a Flow Intermittency Bioreactor for Tissue Engi (30) Foreign Application Priority Data neering Cartilage.
    [Show full text]
  • Pharmacological Treatment Options for Alcohol Use Disorder*
    Dusunen Adam The Journal of Psychiatry and Neurological Sciences 2015;28:283-300 Editorial / Editoryal DOI: 10.5350/DAJPN20152804001 Pharmacological Treatment Cuneyt Evren1, Muge Bozkurt2 1Assoc. Prof. Dr., 2Psychiatrist, Bakirkoy Training and Options for Alcohol Use Research Hospital for Psychiatry, Neurology and Neurosurgery, Alcohol and Drug Research, Treatment and Training Center (AMATEM), Disorder* Istanbul - Turkey Address reprint requests to / Yazışma adresi: Assoc. Prof. Dr. Cuneyt Evren, Bakirkoy Training and Research Hospital for Psychiatry, Neurology and Neurosurgery, Alcohol and Drug Research, Treatment and Training Center (AMATEM), Istanbul, Turkey Phone / Telefon: +90-212-409-1515/2111, Fax / Faks: +90-212-409-1590, E-mail address / Elektronik posta adresi: [email protected] *Abridged version of the “Therapeutic Guideline for Alcohol Use Disorder” prepared by the Working Group Therapeutic Guideline for Alcohol Use Disorder. PHARMACOLOGICAL TREATMENT assess information obtained from studies regarding OPTIONS FOR ALCOHOL USE DISORDER drug treatments used in clinical practice today, which are summarized in Table 1. However, when examining Alcohol Use Disorder (AUD) and other alcohol- study results for pharmacological treatments, we related health problems are a significant public health immediately have to remember that all of those issue all over the world. The World Health Organization (WHO) reports that each year 3.3 million people lose Table 1: Drugs used for the therapy of alcohol use their lives due to harmful alcohol use, with 5.9% of all disorder (AUD) deaths being related to alcohol consumption (1). It has Drugs for AUD approved in Turkey been estimated that in 2010, the economic burden of Disulfiram Naltrexone alcohol-related costs was 155.8 billion Euro, of which Acamprosate 60% were connected to alcohol addiction (2).
    [Show full text]
  • Preferred Drug List 4-Tier
    Preferred Drug List 4-Tier 21NVHPN13628 Four-Tier Base Drug Benefit Guide Introduction As a member of a health plan that includes outpatient prescription drug coverage, you have access to a wide range of effective and affordable medications. The health plan utilizes a Preferred Drug List (PDL) (also known as a drug formulary) as a tool to guide providers to prescribe clinically sound yet cost-effective drugs. This list was established to give you access to the prescription drugs you need at a reasonable cost. Your out- of-pocket prescription cost is lower when you use preferred medications. Please refer to your Prescription Drug Benefit Rider or Evidence of Coverage for specific pharmacy benefit information. The PDL is a list of FDA-approved generic and brand name medications recommended for use by your health plan. The list is developed and maintained by a Pharmacy and Therapeutics (P&T) Committee comprised of actively practicing primary care and specialty physicians, pharmacists and other healthcare professionals. Patient needs, scientific data, drug effectiveness, availability of drug alternatives currently on the PDL and cost are all considerations in selecting "preferred" medications. Due to the number of drugs on the market and the continuous introduction of new drugs, the PDL is a dynamic and routinely updated document screened regularly to ensure that it remains a clinically sound tool for our providers. Reading the Drug Benefit Guide Benefits for Covered Drugs obtained at a Designated Plan Pharmacy are payable according to the applicable benefit tiers described below, subject to your obtaining any required Prior Authorization or meeting any applicable Step Therapy requirement.
    [Show full text]
  • Antimicrotubule Effects of Estramustine, an Antiprostatic Tumor Drug
    [CANCER RESEARCH 45, 3891-3897, August 1985] Antimicrotubule Effects of Estramustine, an Antiprostatic Tumor Drug Mark E. Stearns1 and Kenneth D. Tew2 Departments of Anatomy [M. E. S.] and of Medicine and Pharmacology [K. D, T.], Vincent T. Lombardi Cancer Research Center, Georgetown University Hospital, Washington, DC 20007 ABSTRACT cytomatrix effects of EM and learn how cytoplasmic related effects of EM might ultimately produce the reported antimitotic Estramustine [170-estradiol 3 N bis(2-chloroethyl)carbamate; events in dividing cells (6). EM] is a stable conjugate of estradiol and nor-nitrogen mustard In this paper, we have investigated possible cytotoxic effects that is used for the treatment of human prostatic carcinoma. We of EM at the cytological level. For these studies, the fish erythro- have studied the cytotoxic effects of EM on the cytoskeletal phore or red pigment cell has been used as a model system for organization of squirrelfish pigment cells (erythrophores) and investigation of the cytotoxic consequences of EM. There are a human prostatic tumor cells (DU 145) in culture. Light and whole- number of attractive reasons for utilizing erythrophores for the mount electron microscopy studies reveal that, at /¿Mlevels(60 work described here. Erythrophores are symmetrical cells with to 120 ¿IM),EMhas a dose-dependent disruptive effect on cell thousands of radially ordered microtubules which control the shape, cytoskeletal organization, and intracellular transport. directed motion of numerous red pigment granules (14, 19). At Upon removal of the drug, the cytological effects of EM are the light microscopic level, the pigment is observed to pulsate or rapidly reversible in fish cells but not DU 145s.
    [Show full text]
  • Order in Council 1243/1995
    PROVINCE OF BRITISH COLUMBIA ORDER OF THE LIEUTENANT GOVERNOR IN COUNCIL Order in Council No. 12 4 3 , Approved and Ordered OCT 121995 Lieutenant Governor Executive Council Chambers, Victoria On the recommendation of the undersigned, the Lieutenant Governor, by and with the advice and consent of the Executive Council, orders that Order in Council 1039 made August 17, 1995, is rescinded. 2. The Drug Schedules made by regulation of the Council of the College of Pharmacists of British Columbia, as set out in the attached resolution dated September 6, 1995, are hereby approved. (----, c" g/J1"----c- 4- Minister of Heal fandand Minister Responsible for Seniors Presidin Member of the Executive Council (This pan is for adnwustratlye purposes only and is not part of the Order) Authority under which Order Is made: Act and section:- Pharmacists, Pharmacy Operations and Drug Scheduling Act, section 59(2)(1), 62 Other (specify): - Uppodukoic1enact N6145; Resolution of the Council of the College of Pharmacists of British Columbia ("the Council"), made by teleconference at Vancouver, British Columbia, the 6th day of September 1995. RESOLVED THAT: In accordance with the authority established in Section 62 of the Pharmacists, Pharmacy Operations and Drug Scheduling Act of British Columbia, S.B.C. Chapter 62, the Council makes the Drug Schedules by regulation as set out in the attached schedule, subject to the approval of the Lieutenant Governor in Council. Certified a true copy Linda J. Lytle, Phr.) Registrar DRUG SCHEDULES to the Pharmacists, Pharmacy Operations and Drug Scheduling Act of British Columbia The Drug Schedules have been printed in an alphabetical format to simplify the process of locating each individual drug entry and determining its status in British Columbia.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Emcyt® Estramustine Phosphate Sodium Capsules DESCRIPTION
    Emcyt® estramustine phosphate sodium capsules DESCRIPTION Estramustine phosphate sodium, an antineoplastic agent, is an off-white powder readily soluble in water. EMCYT Capsules are white and opaque, each containing estramustine phosphate sodium as the disodium salt monohydrate equivalent to 140 mg estramustine phosphate, for oral administration. Each capsule also contains magnesium stearate, silicon dioxide, sodium lauryl sulfate, and talc. Gelatin capsule shells contain the following pigment: titanium dioxide. Chemically, estramustine phosphate sodium is estra-1,3,5(10)-triene-3,17-diol(17ß)-,3­ [bis(2-chloroethyl)carbamate] 17-(dihydrogen phosphate), disodium salt, monohydrate. It is also referred to as estradiol 3-[bis(2-chloroethyl)carbamate] 17-(dihydrogen phosphate), disodium salt, monohydrate. Estramustine phosphate sodium has an empiric formula of C23H30Cl2NNa2O6P•H2O, a calculated molecular weight of 582.4, and the following structural formula: CLINICAL PHARMACOLOGY Estramustine phosphate (Figure 1) is a molecule combining estradiol and nornitrogen mustard by a carbamate link. The molecule is phosphorylated to make it water soluble. 1 Estramustine phosphate taken orally is readily dephosphorylated during absorption, and the major metabolites in plasma are estramustine (Figure 2), the estrone analog (Figure 3), estradiol, and estrone. Prolonged treatment with estramustine phosphate produces elevated total plasma concentrations of estradiol that fall within ranges similar to the elevated estradiol levels found in prostatic cancer patients given conventional estradiol therapy. Estrogenic effects, as demonstrated by changes in circulating levels of steroids and pituitary hormones, are similar in patients treated with either estramustine phosphate or conventional estradiol. 2 The metabolic urinary patterns of the estradiol moiety of estramustine phosphate and estradiol itself are very similar, although the metabolites derived from estramustine phosphate are excreted at a slower rate.
    [Show full text]
  • Toxicological Profile for Carbon Tetrachloride
    CARBON TETRACHLORIDE 27 3. HEALTH EFFECTS 3.1 INTRODUCTION The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and other interested individuals and groups with an overall perspective on the toxicology of carbon tetrachloride. It contains descriptions and evaluations of toxicological studies and epidemiological investigations and provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health. A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE To help public health professionals and others address the needs of persons living or working near hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, developmental, genotoxic, and carcinogenic effects). These data are discussed in terms of three exposure periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). Levels of significant exposure for each route and duration are presented in tables and illustrated in figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest­ observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, or those whose significance to the organism is not entirely clear.
    [Show full text]